Reprogramming immunity: the promise and challenges of CAR T cell therapy in multiple sclerosis
Early results suggest CAR-T cell therapy can reset immunity in severe multiple sclerosis, with manufacturing advances addressing scalability challenges.
This review synthesizes the mechanistic rationale and early clinical evidence for CD19-targeted CAR-T as an immunological reset for refractory MS, showing promising sustained remission data from first clinical tests. Engineering advances including allogeneic manufacturing and CRISPR-based safety switches address scalability challenges ahead of broader trials.
What the study was
- Study design
- Narrative review
- Population
- Refractory multiple sclerosis patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Inflammopharmacology
Why it surfaced
CAR-T expanding to autoimmune disease (MS) — emerging watchlist extension; early clinical remission data notable.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.